A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Potential Antiseizure Activity of Adjunctive OV329 Therapy in Adults with Drug-Resistant Focal Epilepsy

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525896-23-00

Enrollment

Registered

2026-08-21

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Focal epilepsy

Brief summary

Incidence, severity, and temporal profile of treatment-emergent AEs (TEAEs)., Incidence of clinically significant abnormalities in vital signs, 12-lead ECGs, clinical laboratory test results, and physical examinations., Incidence of treatment-emergent suicidal ideation and/or suicidal behavior as assessed by the C-SSRS.

Interventions

DRUGOV329

DRUGPlacebo is identical to the IMP but with no active substance.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence, severity, and temporal profile of treatment-emergent AEs (TEAEs)., Incidence of clinically significant abnormalities in vital signs, 12-lead ECGs, clinical laboratory test results, and physical examinations., Incidence of treatment-emergent suicidal ideation and/or suicidal behavior as assessed by the C-SSRS.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 22, 2026